[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2988743T3 - Heterocykliske forbindelser, der kan anvendes til behandling af sygdom - Google Patents

Heterocykliske forbindelser, der kan anvendes til behandling af sygdom Download PDF

Info

Publication number
DK2988743T3
DK2988743T3 DK14762555.2T DK14762555T DK2988743T3 DK 2988743 T3 DK2988743 T3 DK 2988743T3 DK 14762555 T DK14762555 T DK 14762555T DK 2988743 T3 DK2988743 T3 DK 2988743T3
Authority
DK
Denmark
Prior art keywords
heterocyclic compounds
disease treatment
disease
treatment
heterocyclic
Prior art date
Application number
DK14762555.2T
Other languages
English (en)
Inventor
Graham Beaton
Fabio C Tucci
Satheesh B Ravula
Chandravadan R Shah
Hiep Luu
Original Assignee
Epigen Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigen Biosciences Inc filed Critical Epigen Biosciences Inc
Application granted granted Critical
Publication of DK2988743T3 publication Critical patent/DK2988743T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK14762555.2T 2013-03-15 2014-03-17 Heterocykliske forbindelser, der kan anvendes til behandling af sygdom DK2988743T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361801426P 2013-03-15 2013-03-15
US201361801231P 2013-03-15 2013-03-15
US201361827409P 2013-05-24 2013-05-24
PCT/US2014/030712 WO2014145873A2 (en) 2013-03-15 2014-03-17 Heterocyclic compounds useful in the treatment of disease

Publications (1)

Publication Number Publication Date
DK2988743T3 true DK2988743T3 (da) 2021-03-01

Family

ID=51538557

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14762555.2T DK2988743T3 (da) 2013-03-15 2014-03-17 Heterocykliske forbindelser, der kan anvendes til behandling af sygdom

Country Status (16)

Country Link
US (5) US10000459B2 (da)
EP (1) EP2988743B1 (da)
JP (3) JP6482086B2 (da)
KR (1) KR102090231B1 (da)
CN (3) CN105142635B (da)
AU (3) AU2014232383B2 (da)
BR (2) BR112015023267B1 (da)
CA (1) CA2906931C (da)
DK (1) DK2988743T3 (da)
EA (1) EA033923B1 (da)
ES (1) ES2855173T3 (da)
HK (1) HK1221167A1 (da)
MX (2) MX2015013303A (da)
PT (1) PT2988743T (da)
SG (3) SG10201803833WA (da)
WO (1) WO2014145873A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201803833WA (en) * 2013-03-15 2018-06-28 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
EP3378491A4 (en) * 2015-11-20 2019-07-17 UBE Industries, Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF NASH
KR102292989B1 (ko) 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
WO2019126103A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
JP7256807B2 (ja) * 2017-12-19 2023-04-12 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール
ES2898364T3 (es) 2017-12-19 2022-03-07 Bristol Myers Squibb Co Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA
EP3728222B1 (en) * 2017-12-19 2023-03-29 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
CN111699180A (zh) 2017-12-19 2020-09-22 百时美施贵宝公司 作为lpa拮抗剂的吡唑n-连接的氨基甲酰基环己基酸
ES2943661T3 (es) * 2017-12-19 2023-06-15 Bristol Myers Squibb Co Acidos carbamoil ciclohexílicos pirazol-O-ligados como antagonistas de LPA
EP3728210A1 (en) * 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7369125B2 (ja) * 2017-12-19 2023-10-25 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのイソキサゾールｏ－架橋カルバモイルシクロヘキシル酸
WO2019126086A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
CA3104465A1 (en) * 2018-06-18 2019-12-26 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
WO2021076961A1 (en) * 2019-10-16 2021-04-22 University Of South Florida Compositions and methods of treatment for inhibiting capillary tube regression
US11548871B2 (en) 2019-11-15 2023-01-10 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
CN115989220A (zh) * 2020-07-16 2023-04-18 奇斯药制品公司 作为lpa受体抑制剂的酰氨基环己烷酸衍生物
IL300525A (en) * 2020-08-11 2023-04-01 Viva Star Biosciences Ltd Triazole-pyridinyl-substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists
CA3218917A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN118541360A (zh) 2021-12-08 2024-08-23 吉利德科学公司 Lpa受体拮抗剂及其用途
WO2024112895A1 (en) * 2022-11-24 2024-05-30 Lhotse Bio, Inc. Compounds and compositions for treating conditions associated with lpa receptor activity

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
ES2320320T3 (es) 2000-02-18 2009-05-21 Kyowa Hakko Kirin Co., Ltd. Nuevos compuestos de isoxazol y tiazol y uso de los mismos como farmacos.
WO2002062389A1 (fr) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
CA2487315A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
TW200508215A (en) 2003-06-11 2005-03-01 Sankyo Co Cyclic tertiary amine compounds
JP4692281B2 (ja) 2003-08-05 2011-06-01 味の素株式会社 新規アゾール化合物
WO2005044785A1 (en) 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
AU2005225524B2 (en) 2004-03-26 2007-11-22 F. Hoffmann-La Roche Ag Tetrahydrocarbazoles and derivatives
US7897607B2 (en) 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
NZ564916A (en) * 2005-06-27 2011-03-31 Exelixis Inc Imidazole based LXR modulators
TW200803740A (en) * 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
WO2008062739A1 (fr) 2006-11-20 2008-05-29 Japan Tobacco Inc. Pyrazoles et leur utilisation en tant que médicaments
CN101821239B (zh) 2007-10-18 2014-01-01 组合化学工业株式会社 3-烷氧基-1-苯基吡唑衍生物及有害生物防除剂
WO2010004507A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (en) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
JP4683154B2 (ja) 2009-08-12 2011-05-11 横浜ゴム株式会社 冷媒移送用ホース
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
US20130253019A1 (en) 2010-06-15 2013-09-26 John Howard Hutchinson Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
WO2011159635A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
US20120031985A1 (en) 2010-08-09 2012-02-09 Terry Lien Do Fault tolerant appliance
SG190417A1 (en) * 2010-12-07 2013-07-31 Amira Pharmaceuticals Inc Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
MX347544B (es) 2010-12-07 2017-05-02 Bristol Myers Squibb Co Antagonista de acido lisofostatidico 1 (lpa1) policiclico y usos del mismo.
CN103443098B (zh) * 2011-01-30 2016-03-16 广州源生医药科技有限公司 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
JP2014525932A (ja) * 2011-08-15 2014-10-02 インターミューン， インコーポレイテッド リゾホスファチド酸レセプターアンタゴニスト
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
US20140329871A1 (en) 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
US9499538B2 (en) 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US20150133512A1 (en) 2012-06-20 2015-05-14 Hoffmann-La Roche Inc, N-aryltriazole compounds as lpar antagonists
MX2014014105A (es) 2012-06-20 2015-03-05 Hoffmann La Roche Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar).
US9321738B2 (en) 2012-06-20 2016-04-26 Hoffman-La Roche Inc. N-alkyltriazole compounds as LPAR antagonists
MX369801B (es) 2012-12-28 2019-11-21 Ube Industries Compuesto heterociclico sustituido con halogeno.
TW201437200A (zh) 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
SG10201803833WA (en) * 2013-03-15 2018-06-28 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
US9987381B2 (en) 2013-10-31 2018-06-05 Bristol-Myers Squibb Company Radioligands for imaging the LPA-1 receptor
MX370408B (es) 2014-06-27 2019-12-11 Ube Industries Sal de compuesto heterociclico sustituido con halogeno.

Also Published As

Publication number Publication date
JP2016515536A (ja) 2016-05-30
WO2014145873A2 (en) 2014-09-18
EP2988743A4 (en) 2016-11-30
CN112424174B (zh) 2024-02-27
ES2855173T3 (es) 2021-09-23
CN118290357A (zh) 2024-07-05
NZ712889A (en) 2020-10-30
AU2019288275B2 (en) 2024-08-01
US20200181099A1 (en) 2020-06-11
SG11202012656WA (en) 2021-01-28
KR102090231B1 (ko) 2020-03-17
SG11201507459YA (en) 2015-10-29
JP6482086B2 (ja) 2019-03-13
WO2014145873A3 (en) 2014-12-18
JP2019081784A (ja) 2019-05-30
CA2906931A1 (en) 2014-09-18
US20160024031A1 (en) 2016-01-28
PT2988743T (pt) 2021-03-03
MX2015013303A (es) 2015-12-15
CN105142635B (zh) 2021-07-27
EA201591607A8 (ru) 2018-03-30
HK1221167A1 (zh) 2017-05-26
BR112015023267A2 (pt) 2017-07-18
US20230286928A1 (en) 2023-09-14
AU2019288275A1 (en) 2021-01-28
CA2906931C (en) 2023-03-14
CN105142635A (zh) 2015-12-09
AU2014232383A1 (en) 2015-10-01
AU2014232383B2 (en) 2019-01-17
AU2019202731B2 (en) 2020-10-29
KR20150130415A (ko) 2015-11-23
US10570103B2 (en) 2020-02-25
US10000459B2 (en) 2018-06-19
US20180297962A1 (en) 2018-10-18
EP2988743A2 (en) 2016-03-02
JP6843903B2 (ja) 2021-03-17
US11427552B2 (en) 2022-08-30
JP2024084796A (ja) 2024-06-25
US10526298B2 (en) 2020-01-07
CN112424174A (zh) 2021-02-26
AU2019202731A1 (en) 2019-05-16
BR112015023267A8 (pt) 2021-04-13
BR112020025927A2 (pt) 2021-03-23
EA201591607A1 (ru) 2016-05-31
MX2020014300A (es) 2021-05-12
EA033923B1 (ru) 2019-12-10
EP2988743B1 (en) 2020-12-09
US20190135767A1 (en) 2019-05-09
SG10201803833WA (en) 2018-06-28
BR112015023267B1 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
DK2988743T3 (da) Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
DK3436444T3 (da) Heterocyklisk forbindelse
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
CL2016002129A1 (es) Compuestos de azolina
DK3110418T3 (da) Aryl-, heteroaryl- og heterocykliske-forbindelser til behandling af komplemt-medierede lidelser
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK2984166T3 (da) Sammensætninger til behandling af mpsi
BR112016010220A2 (pt) compostos inibidores de autoxatina.
DK2970336T3 (da) Tetrahydropyrrolothiazinforbindelser
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK3007726T3 (da) Fremgangsmåder til behandling af en tauopati
DK2967049T3 (da) Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
DK3016493T3 (da) Behandling til desinficering af frø
DK3350463T3 (da) Drejeleje
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK3373931T3 (da) Heterocykliske forbindelser til behandling af sygdom
DK3597189T3 (da) Krystallinske forbindelser
BR112016002563A2 (pt) compostos químicos.
DK3368519T3 (da) Hidtil ukendte, heterocykliske antiøstrogener
CL2016000616A1 (es) Compuestos heterocíclicos de n-acilimino.
ES1157711Y (es) Filtro
DK2986325T3 (da) Fremgangsmåder til behandling af forstyrrelser i urinstofcyklus
DK3016682T3 (da) Metoder til behandling af kræft